25周年を記念 1999-2024
*3年間で¥ 153396、たったの¥ 61358
フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Mallinckrodt to Present at Jefferies London Healthcare Conference PR Newswire DUBLIN, Nov. 14, 2024 DUBLIN...
Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance PR...
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for...
Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals PR...
Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®...
THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device...
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance PR...
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled...
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million PR Newswire DUBLIN and...
Mallinckrodt to Report Earnings Results for Second Quarter 2024 PR Newswire DUBLIN, Aug. 1, 2024 DUBLIN, Aug...
Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations PR...
Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan PR...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約